<DOC>
	<DOCNO>NCT02088554</DOCNO>
	<brief_summary>To evaluate safety effectiveness Model 400 aortic valve bioprosthesis .</brief_summary>
	<brief_title>PERIGON Pivotal Trial</brief_title>
	<detailed_description>This prospective , interventional , non-randomized , worldwide , multi-center trial , site follow common protocol . A maximum 1300 subject implant maximum 40 site US , Europe Canada . The trial include male female patient legal age provide inform consent country enroll trial , require replacement diseased , damage , malfunction native prosthetic aortic valve . Patients follow assessed implant 5 year .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patient moderate great aortic stenosis regurgitation , clinical indication replacement native prosthetic aortic valve bioprosthesis , without concomitant procedure , limit following : i. LAA ligation ii . CABG iii . PFO closure iv . Ascending aortic aneurysm dissection repair require circulatory arrest v. Resection subaortic membrane require myectomy 2 . Patient geographically stable willing return implant site followup visit 3 . Patient legal age provide inform consent country enroll trial 4 . Patient adequately inform risk requirement trial willing able provide inform consent participation clinical trial 1 . Patient preexist prosthetic valve annuloplasty device another position require replacement repair mitral , pulmonary tricuspid valve 2 . Patient previous implant explant Model 400 aortic valve bioprosthesis 3 . Patient present active endocarditis , active myocarditis systemic infection 4 . Patient anatomical abnormality would increase surgical risk morbidity mortality , include : Ascending aortic aneurysm dissection repair require circulatory arrest Acute Type A aortic dissection Ventricular aneurysm Porcelain aorta Hostile mediastinum Hypertrophic obstructive cardiomyopathy ( HOCM ) Documented pulmonary hypertension ( systolic &gt; 60mmHg ) 5 . Patient noncardiac major progressive disease , life expectancy le 2 year . These condition include , limited : ChildPugh Class C liver disease Terminal cancer Endstage lung disease 6 . Patient renal failure , define dialysis therapy GFR &lt; 30 mL/min/1.73 m2 7 . Patient hyperparathyroidism 8 . Patient participate another investigational device drug trial observational competitive study 9 . Patient pregnant , lactate plan become pregnant trial period 10 . Patient document history substance ( drug alcohol ) abuse 11 . Patient great mild mitral valve regurgitation great mild tricuspid valve regurgitation assess echocardiography 12 . Patient systolic EF &lt; 20 % assess echocardiography 13 . Patient Grade IV Diastolic Dysfunction 14 . Patient document bleeding diatheses 15 . Patient acute preoperative neurological deficit myocardial infarction return baseline stabilize â‰¥30 day prior enrollment 16 . Patient require emergency surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>